

Covered Genetic Testing That Does Not Require a Prior Authorization

Policy	Test Name	Updated: 10/01/2022
Thrombophilia	Factor V Leiden – F5 Gene 1691>A mutation	
Thrombophilia	Prothrombin - F2 Gene G20210A mutation	
Reproductive	Spinal Muscular Atrophy (SMA) – SMN1 gene	
Reproductive	Karyotype (cytogenetic analysis) for recurrent pregnancy loss.	
Reproductive	Karyotype and/or microarray of abortus tissue	
Reproductive	Anti-Beta2-Glycoprotein I Antibodies	
Reproductive	anti-Cardiolipin (IgG or IgM) Antibodies	
Reproductive	Lupus anticoagulant	
Reproductive	Non-invasive prenatal testing (NIPT): trisomy 13, 18 or 21 (e.g. MaterniT21)	
Reproductive	Invasive Prenatal Testing of a Fetus	
Reproductive	Cystic Fibrosis Carrier Screening and Cystic Fibrosis Sequencing Deletion/Duplication	
Reproductive	Chromosome Microarray Analysis (CMA) Prenatal Testing	
Reproductive	Cystic Fibrosis Carrier Screening and sequencing and deletion/duplication studies	
Reproductive	Ashkenazi Jewish Carrier Screening – Cystic fibrosis, familial dysautonomia, Tay Sachs disease, Canavan disease, Fanconi anemia group C, Niemann-Pick disease, Bloom syndrome, Mucopolysaccharidosis type IV, Gaucher disease, type 1	
Reproductive	Single Gene Reproductive Carrier Screen for familial genetic disorder	
Somatic Tumor	Acute Lymphoblastic Leukemia – BCR-ALB1 Fusion	
Somatic Tumor	Acute Promyelocytic Leukemia – PML-RARA Fusion	
Somatic Tumor	Chronic Eosinophilic Leukemia/Hypereosinophilic Syndrome - FIP1L1-PDGFRα	
Somatic Tumor	Chronic Myelogenous Leukemia - BCR-ALB1 Fusion	
Somatic Tumor	Lynch Syndrome Colorectal Tumor Analysis – BRAF V600E MLH1	
Somatic Tumor	Microsatellite Instability (MSI) Testing of Endometrial Tissue	
Somatic Tumor	Metastatic Colorectal Tumor tests: NRAS, KRAS , BRAF or V600E	
Somatic Tumor	Malignant Melanoma in Tumor: BRAF V600	
Somatic Tumor	Localized Uveal Melanoma: Gene expression profiling risk stratification Decision Dx-UM	
Somatic Tumor	Myelodysplastic Syndrome – TET2, DNMT3A, TP53, SF3B1, SRSF2, U2AF1, ZRSR2, ASXL1, RUNX1, EZH2, NRAS, CBL, JAK2, SETBP1, IDH1, IDH2, ETV6	
Somatic Tumor	Myeloproliferative Neoplasms - Janus Kinase 2 (JAK2)	

Covered Genetic Testing That Does Not Require a Prior Authorization

Somatic Tumor	Myeloproliferative Neoplasms - MPL exon 9 and CALR
Somatic Tumor	Mammaprint 70-Gene Breast Cancer Recurrence Assay and Mammaprint Microarray Test
Somatic Tumor	Colon Cancer – Oncotype DX Colon Cancer Assay, Oncotype DX Recurrence Score, Colon Cancer Gene Expression Assay (GeneFx Colon and ColoPrint)
Somatic Tumor	Guardant360 Circulating Tumor DNA Liquid Biopsy Test (non-small cell lung cancer)
Somatic Tumor	Prostate Cancer Molecular Tumor Testing - Oncotype DX Genomic Prostate Score Assay, Decipher Prostate Cancer Classifier Assay, Prolaris Biopsy Test, ProMark Proteomic Prognostic Test, ,
Somatic Tumor	Prostate Cancer Screening and Prognostic Tests – ExoDxProstate/ExsomeDxProstate, SelectMDx (Intelliscore), Progensa PCA 3 Assay, 4K score, Prostate Health Index, IsoPSA Test, ConfirmMDx
Somatic Tumor	Oncotype DX Breast Cancer Assay, Oncotype DX Breast Recurrence Score
Somatic Tumor	EndoPredict Breast Cancer Recurrence
Somatic Tumor	Prosigna Breast Cancer Prognostic Gene Signature Assay
Somatic Tumor	MyChoice CDx Tumor Test
Somatic Tumor	Non-Small Cell Lung Cancer - EGFR, KRAS, HER2, BRAF V600E, ROS-1, RET, MET
Somatic Tumor	Thyroid Nodule Gene Expression Testing - Afirma Thyroid FNA Analysis, Affirma GSC, ThyraMir or Interpace ThyGenX Oncogene Panel
Chromosomal Microarray Analysis	Chromosomal Microarray Analysis (CMA)
General	Alpha-1 antitrypsin deficiency (SERPINA1)
General	Fragile X Syndrome (FMR1)
General	Hereditary Hemochromatosis - HFE Gene
General	Inflammatory Bowel Disease – TPMT Gene
High Penetrance Breast and/or Epithelial Ovarian Cancer Susceptibility	BRCA1 and BRCA2, BRACAnalysis CDx
Pharmacogenetics	AlloMap Gene Expression Profile
Pharmacogenetics	Discrete Targeted Genetic Testing for Drug Therapy (cancer related drugs) (refer to policy)
Pharmacogenetics	FoundationOne CDx
Pharmacogenetics	Targeted Genetic Testing for Drug Therapy (excludes cancer related drugs) (refer to policy)
Pharmacogenetics	HLA-B*5701 for HIV-1 before starting treatment with ZIAGEN (abacavir); HLA-B*1502 for persons Asian ancestry before starting treatment with Tegretol, Dilantin or Allopurinol